Zobrazeno 1 - 10 of 271 pro vyhledávání: '"R S, Doody"'
1
Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer’s Disease
Autor: R. S. Doody, P. J. Massman, X. Fu, X. Wang, M. Ke, Yang Lü, W. Yu, J. Zhang, T. Luo
Publikováno v: The Journal of Prevention of Alzheimer's Disease. :1-6
BACKGROUND: A specialized instrument for assessing the cognition of patients with severe Alzheimer’s disease (AD) is needed in China. Objectives: To validate the Chinese version of the Baylor Profound Mental Status Examination (BPMSE-Ch). Design: T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d11c802300a5ac2878f0daafb0fca76
https://doi.org/10.14283/jpad.2020.72
Zobrazit plný text záznamu
3
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Autor: H H, Feldman, R S, Doody, M, Kivipelto, D L, Sparks, D D, Waters, R W, Jones, E, Schwam, R, Schindler, J, Hey-Hadavi, D A, DeMicco, A, Breazna, P P, Zolnouni
Publikováno v: Neurology. 74:956-964
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4567ed6ec2232c71e3dd945d1b53dd
https://doi.org/10.1212/wnl.0b013e3181d6476a
Zobrazit plný text záznamu
4
Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Autor: R S, Doody, S H, Ferris, S, Salloway, Y, Sun, R, Goldman, W E, Watkins, Y, Xu, A K, Murthy
Publikováno v: Neurology. 72:1555-1561
Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::949a00bb79c550bc16e315d1dc03a39c
https://doi.org/10.1212/01.wnl.0000344650.95823.03
Zobrazit plný text záznamu
6
Akademický článek
Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy.
Autor: Gong B; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Zhang W; School of Pharmacy, University College London, London, WC1N 1AX, UK., Cong W; School of Medicine, Shanghai University, Shanghai, 200444, China., Gu Y; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Ji W; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Yin T; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Zhou H; Department of General Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Hu H; School of Medicine, Shanghai University, Shanghai, 200444, China., Zhuang J; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China., Luo Y; New Drug Discovery and Development, Biotheus Inc., Zhuhai, 519080, China.; Clinical Pharmacy Innovation Institute, Shanghai Jiao Tong University of Medicine, Shanghai, 200240, China., Liu Y; Clinical Pharmacy Innovation Institute, Shanghai Jiao Tong University of Medicine, Shanghai, 200240, China.; Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China., Gao J; Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Yin Y; Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.; Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Publikováno v: Advanced healthcare materials [Adv Healthc Mater] 2024 Jul 15, pp. e2400149. Date of Electronic Publication: 2024 Jul 15.
Zobrazit plný text záznamu
7
Akademický článek
Bio-Nano Toolbox for Precision Alzheimer's Disease Gene Therapy.
Autor: Liu Y; Department of Radiotherapy and Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, 475000, China.; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China., Xia X; Department of Radiotherapy and Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, 475000, China.; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China.; Macquarie Medical School, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, New South Wales, 2109, Australia., Zheng M; Department of Radiotherapy and Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, 475000, China.; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China., Shi B; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China.; Macquarie Medical School, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, New South Wales, 2109, Australia.
Publikováno v: Advanced materials (Deerfield Beach, Fla.) [Adv Mater] 2024 Jul; Vol. 36 (29), pp. e2314354. Date of Electronic Publication: 2024 May 22.
Zobrazit plný text záznamu
9
Therapeutic standards in Alzheimer disease
Autor: R S, Doody
Publikováno v: Alzheimer disease and associated disorders. 13
Donepezil is an effective, well-tolerated, and easily administered symptomatic treatment for mild-to-moderate Alzheimer disease (AD). Data from Phase III clinical trials have demonstrated that donepezil improves cognition, global function, and activi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0547f6dcf2ab59767e846074a2f2a8d9
https://pubmed.ncbi.nlm.nih.gov/10622675
Zobrazit plný text záznamu
10
Efficacy of donepezil in Alzheimer's disease: fact or artifact?
Autor: W. A. van Gool, S. L. Rogers, L. T. Friedhoff, M. R. Farlow, R. S. Doody, R. Mohs
Publikováno v: Neurology. 52(1)
To the Editor: From their study of donepezil, Rogers et al. conclude that this drug is “efficacious in treating symptoms of memory and cognitive loss in patients with mild to moderately severe AD.”1 The following characteristics of their methodol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2788355cda15cb628041f0c6e17d4f
https://pubmed.ncbi.nlm.nih.gov/9443470
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje